179 related articles for article (PubMed ID: 26034208)
1. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism.
Rogalska-Taranta M; Markova AA; Taranta A; Lunemann S; Schlaphoff V; Flisiak R; Manns MP; Cornberg M; Kraft AR; Wedemeyer H
J Leukoc Biol; 2015 Aug; 98(2):283-94. PubMed ID: 26034208
[TBL] [Abstract][Full Text] [Related]
2. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
Edlich B; Ahlenstiel G; Zabaleta Azpiroz A; Stoltzfus J; Noureddin M; Serti E; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2012 Jan; 55(1):39-48. PubMed ID: 21898483
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
4. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection.
Miyagi T; Takehara T; Nishio K; Shimizu S; Kohga K; Li W; Tatsumi T; Hiramatsu N; Kanto T; Hayashi N
J Hepatol; 2010 Sep; 53(3):424-30. PubMed ID: 20554341
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.
Indolfi G; Azzari C; Resti M
World J Gastroenterol; 2014 Jul; 20(28):9245-52. PubMed ID: 25071317
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
7. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
[TBL] [Abstract][Full Text] [Related]
8. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
9. Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C.
Imoto S; Kim SR; Amano K; Iio E; Yoon S; Hirohata S; Yano Y; Ishikawa T; Katsushima S; Komeda T; Fukunaga T; Chung H; Kokuryu H; Horie Y; Hatae T; Fujinami A; Kim SK; Kudo M; Tanaka Y
Dig Dis; 2017; 35(6):531-540. PubMed ID: 29040985
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
11. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
13. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.
O'Connor KS; Read SA; Wang M; Schibeci S; Eslam M; Ong A; Weltman MD; Douglas MW; Mazzola A; Craxì A; Petta S; Stewart GJ; Liddle C; George J; Ahlenstiel G; Booth DR
Genes Immun; 2016 Sep; 17(6):328-34. PubMed ID: 27307212
[TBL] [Abstract][Full Text] [Related]
14. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
[TBL] [Abstract][Full Text] [Related]
15. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
[TBL] [Abstract][Full Text] [Related]
16. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
17. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
[TBL] [Abstract][Full Text] [Related]
18. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
[TBL] [Abstract][Full Text] [Related]
19. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
[TBL] [Abstract][Full Text] [Related]
20. IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.
Bordi L; Caglioti C; Garbuglia AR; Lapa D; Castilletti C; Taibi C; Capobianchi MR; Lalle E
PLoS One; 2015; 10(2):e0117397. PubMed ID: 25675103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
